Major indices finish lower amid GE earnings disappointment >>> READ MORE

5 Biotech Stocks With Big Catalysts on the Horizon

Upcoming news could send these biotechs soaring

      View All  


progenics-pgnx-stockThe next-to-last step in bringing a drug all the way through the FDA’s maze is a review by an FDA advisory committee. This committee doesn’t make the final decision, but it does recommend an approval or a rejection, and the Food & Drug Administration generally heeds the advice.

Relistor, from Progenics (PGNX), for opioid-induced constipation, will be scrutinized by the appropriate advisory committee on March 10-11. A constipation treatment might not seem like much of a game-changer for Progenics. This market is surprisingly large, however. See, one of the relatively common side effects of pain-relieving opioids is — you guessed it — constipation.

Some believe Relistor could generate nearly $300 million in various milestones for Progenics.

Article printed from InvestorPlace Media,

©2017 InvestorPlace Media, LLC